Follow-Up After Cannabis Overdose
Reassure the patient that cannabis overdose is not life-threatening (no risk of respiratory depression), provide supportive care for acute symptoms, educate about fall risk and driving restrictions for up to 12 hours, and strongly counsel on cannabis cessation or dose reduction to prevent recurrence 1.
Immediate Post-Overdose Management
Acute Symptom Management
Cannabis overdoses, while distressing, do not carry the respiratory depression risk seen with opioids 1. However, patients remain at high risk for:
- Falls due to dizziness, confusion, and orthostatic hypotension
- Tachycardia and cardiovascular instability
- Severe confusion and paranoia
- Acute anxiety and panic
Monitor vital signs and provide supportive care until symptoms resolve. Common acute effects include sedation, neuroexcitation, tachycardia, and altered mental status 2. The intensity and duration correlate with THC blood concentration 3.
Safety Counseling (Critical First 12 Hours)
Explicitly prohibit driving or operating machinery for up to 12 hours post-ingestion depending on the cannabis product type 1. Cannabis use more than doubles motor vehicle crash risk 1. Patients must arrange safe transportation home and avoid safety-sensitive work.
Outpatient Follow-Up Strategy
Assessment of Cannabis Use Pattern
Document the specific details that predict future complications:
- Frequency: Daily use or >4 times per week significantly increases risk of cannabis hyperemesis syndrome (CHS) and cannabis use disorder 1, 4
- Duration: >1 year of regular use before symptom onset is typical for CHS 4
- Product type: Concentrated products (resins, liquid concentrates, dabs) cause greater toxicity and higher ICU admission rates than plant forms 2
- THC:CBD ratio and administration route (inhaled vs. ingested vs. transdermal) 1
- Source: Formally sourced (dispensary-tested) vs. informal products 1
Distinguish Between Two Key Syndromes
Cannabis Hyperemesis Syndrome (CHS): Cyclic vomiting episodes (≥3 annually) with chronic heavy use (>4 times/week for >1 year), often with compulsive hot bathing behavior 4, 5. Treatment requires complete cannabis cessation 4.
Cannabis Withdrawal Syndrome (CWS): Irritability, restlessness, anxiety, insomnia occurring after cessation in chronic daily users 1, 5. Requires supportive care and may benefit from brief benzodiazepines.
Long-Term Management Plan
Primary intervention: Cannabis cessation counseling 4, 5. This is non-negotiable for preventing recurrence.
For patients with recurrent symptoms or established CHS:
- Tricyclic antidepressants (amitriptyline 75-100 mg at bedtime, starting at 25 mg and titrating weekly) 4
- Topical capsaicin 0.1% cream for symptom relief 4
- Consider referral to addiction specialist or cannabis clinic if primary team lacks expertise 1
Monitor for Complications
If CBD products involved: Check liver enzymes at baseline and 2 months, as CBD causes dose-related transaminase elevations (13% reach 3x upper limit of normal), particularly at doses >300 mg/day 1. One-third resolve spontaneously; others require dose reduction or discontinuation.
Screen for cannabis use disorder: 10% of chronic users develop clinically significant impairment, with difficulty cutting back despite desire to do so 1. Early onset of use and daily consumption strongly predict dependence 1.
Psychiatric Risk Assessment
Cannabis use may exacerbate or trigger:
- Depressive disorders (increased risk with chronic use) 1
- Psychotic disorders in vulnerable individuals 1
- Suicidality in context of heavy use 6
Refer to psychiatry if psychiatric symptoms emerge or worsen.
Patient Education Points
Storage Safety
Prevent accidental re-exposure, especially for children and pets:
- Store separately from regular food/drinks
- Use locked location, out of sight and reach
- Keep in child-resistant packaging 1
Drug Interactions
High-risk interactions requiring monitoring or avoidance:
- Warfarin (very high risk) 1
- Buprenorphine and tacrolimus (high risk) 1
- Potential interactions with chemotherapy agents metabolized by cytochrome P450 1
Avoid Opioids
Do not prescribe opioids for symptom management—they worsen nausea and carry high addiction risk in this population 4.
Common Pitfalls
- Misattributing symptoms to other causes: In chronic cannabis users with refractory nausea/vomiting, always consider CHS rather than pursuing extensive GI workup 4, 7
- Prescribing antiemetics alone: Standard antiemetics (ondansetron, metoclopramide) typically fail in CHS; cessation is the only definitive treatment 4, 7
- Underestimating concentrated products: Edibles and concentrates cause more severe toxicity than plant forms, with higher rates of intubation and ICU admission 2
- Missing withdrawal symptoms: Non-life-threatening but distressing withdrawal occurs in chronic daily users and may require short-term benzodiazepines 1